Impacto de los P-CABs en el tratamiento de las enfermedades relacionadas con el ácido: una revisión de la evidencia
DOI:
https://doi.org/10.52787/agl.v54i2.414Palabras clave:
P-CAB, IBP, enfermedades relacionadas con el ácido, secreción de ácido gástrico, fexuprazan, tegoprazan, vonoprazan, revaprazanResumen
Los bloqueadores ácidos competitivos de potasio (P-CABs), como vonoprazan, fexuprazan, tegoprazan y revaprazan, representan una clase innovadora de medicamentos diseñados para tratar afecciones relacionadas con la secreción de ácido gástrico, incluida la enfermedad por reflujo gastroesofágico (ERGE), la infección por Helicobacter pylori (Hp) y la enfermedad ulcerosa péptica. Estos fármacos actúan inhibiendo de manera reversible y competitiva la bomba de protones H+/K+-ATPasa, lo cual les permite suprimir la producción de ácido gástrico de forma más efectiva y con una rapidez superior en comparación con los inhibidores de la bomba de protones (IBP) tradicionales. Además, estos fármacos no se ven interferidos por la enzima CYP2C19 y su efecto es independiente de la ingesta de alimentos, lo que les confiere ventajas sobre la mayoría de los IBP. Los estudios clínicos han demostrado que los P-CABs son superiores a los IBP en el manejo de la ERGE erosiva severa, y no inferiores en los grados leves y en la enfermedad no erosiva.
Por otra parte, los P-CABs ofrecen tasas de erradicación
de Hp no inferiores y, en algunos casos, superiores a las de
los IBP, en los tratamientos de primera línea, pero no en
los de segunda. En conclusión, los P-CABs emergen como
alternativas prometedoras en el manejo de trastornos gastrointestinales
ácido-dependientes.
Citas
-1. He J, Cao G, Yu J, Wang J, Cheng N, Wu J, et al. Safety, Tolerability and Pharmacokinetics of Single Ascending and Multiple Oral Doses of Tegoprazan in Healthy Chinese Subjects. Clin Drug Investig [Internet]. 2021;41(1):89-97. Disponible en: http://link.springer.com/10.1007/s40261-020-00986-4
-2. Chen D, Hagen SJ, Boyce M, Zhao C. Neuroendocrine mechanism of gastric acid secretion: Historical perspectives and recent developments in physiology and pharmacology. J Neuroendocrinol [Internet]. 2023;35(11). Disponible en: https://onlinelibrary.wiley.com/doi/10.1111/jne.13305
-3. Engevik AC, Kaji I, Goldenring JR. The Physiology of the Gastric Parietal Cell. Physiol Rev [Internet].2020;100(2):573-602. Disponible en: https://journals.physiology.org/doi/10.1152/physrev.00016.2019
-4. Ramsay PT, Carr A. Gastric Acid and Digestive Physiology. Surgical Clinics of North America [Internet].2011;91(5):977-82. Disponible en: https://linkinghub.elsevier.com/retrieve/pii/S0039610911000740
-5. Sobrino-Cossío S, Teramoto-Matsubara O, Mateos-Pérez G, Abdo-Francis JM, Tawil J, Olguín-Ramírez C, et al. In search of the grail: A race for acid suppression. Rev Gastroenterol Mex [Internet]. 2019;84(3):344-56. Disponible en: https://linkinghub.elsevier.com/retrieve/pii/S0375090619300722
-6. Han S, Choi HY, Kim YH, Nam JY, Kim B, Song GS, et al. Effect of Food on the Pharmacokinetics and Pharmacodynamics of a Single Oral Dose of Tegoprazan. Clin Ther [Internet]. 2021;43(8):1371-80. Disponible en: https://linkinghub.elsevier.com/retrieve/pii/S014929182100237X
-7. Hunt RH, Scarpignato C. Potent Acid Suppression with PPIs and P-CABs: What’s New? Curr Treat Options Gastroenterol [Internet]. 2018;16(4):570-90. Disponible en: http://link.springer.com/10.1007/s11938-018-0206-y
-8. Leowattana W, Leowattana T. Potassium-competitive acid blockers and gastroesophageal reflux disease. World J Gastroenterol [Internet].2022;28(28):3608-19. Disponible en: https://www.wjgnet.com/1007-9327/full/v28/i28/3608.htm
-9. Kim TH. Role of potassium-competitive acid blockers in eradication of Helicobacter pylori infection. Korean J Intern Med [Internet].2023;38(4):451-3. Disponible en: http://kjim.org/journal/view.php?doi=10.3904/kjim.2023.250
-10. Han S, Choi HY, Kim YH, Nam JY, Kim B, Song GS, et al. Randomised clinical trial: safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple oral doses of tegoprazan (CJ-12420), a novel potassium-competitive acid blocker, in healthy male subjects. Aliment Pharmacol Ther [Internet]. 2019;50(7):751-9. Disponible en: https://onlinelibrary.wiley.com/doi/10.1111/apt.15438
-11. Hwang JG, Yoo H, Lee JW, Song GS, Lee S, Kim MG. Comparison of pharmacokinetic characteristics of two Tegoprazan (CJ-12420) formulations in healthy male subjects. Transl Clin Pharmacol [Internet].2019;27(2):80. Disponible en: https://tcpharm.org/DOIx.php?id=10.12793/tcp.2019.27.2.80
-12. Oshima T, Miwa H. Potent Potassium-competitive Acid Blockers: A New Era for the Treatment of Acid-related Diseases. J Neurogastroenterol Motil [Internet]. 2018;24(3):334-44. Disponible en: http://www.jnmjournal.org/journal/view.html?doi=10.5056/jnm18029
-13. Scarpignato C, Hunt RH. The potential role of potassium-competitive acid blockers in the treatment of gastroesophageal reflux disease. Curr Opin Gastroenterol [Internet]. 2019;35(4):344-55. Disponible en: https://journals.lww.com/00001574-201907000-00014
-14. Sugano K. Vonoprazan fumarate, a novel potassium-competitive acid blocker, in the management of gastroesophageal reflux disease: safety and clinical evidence to date. Therap Adv Gastroenterol [Internet].2018;11:1756283X1774577. Disponible en: http://journals.sagepub.com/doi/10.1177/1756283X17745776
-15. Shin JM, Inatomi N, Munson K, Strugatsky D, Tokhtaeva E, Vagin O, et al. Characterization of a Novel Potassium-Competitive Acid Blocker of the Gastric H,K-ATPase, 1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1 H -pyrrol-3-yl]-N -methylmethanamine Monofumarate (TAK-438). Journal of Pharmacology and Experimental Therapeutics [Internet].2011;339(2):412-20. Disponible en: http://jpet.aspetjournals.org/lookup/doi/10.1124/jpet.111.185314
-16. Scarpignato C, Hunt RH. Editorial: potassium-competitive acid blockers for acid-related diseases-tegoprazan, a new kid on the block. Aliment Pharmacol Ther [Internet].2019;50(8):960-2. Disponible en: https://onlinelibrary.wiley.com/doi/10.1111/apt.15480
-17. Matsukawa J, Kogame A, Tagawa Y, Inatomi N. Radiographic Localization Study of a Novel Potassium-Competitive Acid Blocker, Vonoprazan, in the Rat Gastric Mucosa. Dig Dis Sci [Internet].2016;61(7):1888-94. Disponible en: http://link.springer.com/10.1007/s10620-016-4100-y
-18. Hori Y, Matsukawa J, Takeuchi T, Nishida H, Kajino M, Inatomi N. A Study Comparing the Antisecretory Effect of TAK-438, a Novel Potassium-Competitive Acid Blocker, with Lansoprazole in Animals. Journal of Pharmacology and Experimental Therapeutics [Internet].2011;337(3):797-804. Disponible en: http://jpet.aspetjournals.org/lookup/doi/10.1124/jpet.111.179556
-19. Echizen H. The First-in-Class Potassium-Competitive Acid Blocker, Vonoprazan Fumarate: Pharmacokinetic and Pharmacodynamic Considerations. Clin Pharmacokinet [Internet]. 2016;55(4):409-18. Disponible en: http://link.springer.com/10.1007/s40262-015-0326-7
-20. Jenkins H, Sakurai Y, Nishimura A, Okamoto H, Hibberd M, Jenkins R, et al. Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK -438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects. Aliment Pharmacol Ther [Internet]. 2015;41(7):636-48. Disponible en: https://onlinelibrary.wiley.com/doi/10.1111/apt.13121
-21. Ashida K, Sakurai Y, Hori T, Kudou K, Nishimura A, Hiramatsu N, et al. Randomised clinical trial: vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis. Aliment Pharmacol Ther [Internet 2016;43(2):240-51. Disponible en: https://onlinelibrary.wiley.com/doi/10.1111/apt.13461
-22. Ashida K, Sakurai Y, Nishimura A, Kudou K, Hiramatsu N, Umegaki E, et al. Randomised clinical trial: a doseranging study of vonoprazan, a novel potassiumcompetitive acid blocker, vs. lansoprazole for the treatment of erosive oesophagitis. Aliment Pharmacol Ther [Internet].2015;42(6):685-95. Disponible en: https://onlinelibrary.wiley.com/doi/10.1111/apt.13331
-23. Ashida K, Iwakiri K, Hiramatsu N, Sakurai Y, Hori T, Kudou K, et al. Maintenance for healed erosive esophagitis: Phase III comparison of vonoprazan with lansoprazole. World J Gastroenterol [Internet].2018;24(14):1550-61. Disponible en: http://www.wjgnet.com/1007-9327/full/v24/i14/1550.htm
-24. Chen M, Dai N, Fei G, Chong CF, Funao N, Zhang S. UEG Week 2018 Poster Presentations. United European Gastroenterol J [Internet].2018;6(S8). Disponible en: https://onlinelibrary.wiley.com/doi/10.1177/2050640618792819
-25. Xiao Y, Zhang S, Dai N, Fei G, Goh KL, Chun HJ, et al. Phase III, randomised, double-blind, multicentre study to evaluate the efficacy and safety of vonoprazan compared with lansoprazole in Asian patients with erosive oesophagitis. Gut [Internet]. 2020;69(2):224-30. Disponible en: https://gut.bmj.com/lookup/doi/10.1136/gutjnl-2019-318365
-26. Okanobu H, Kohno T, Mouri R, Hatsushika Y, Yamashita Y, Miyaki E, et al. Efficacy of vonoprazan 10 mg compared with 20 mg for the initial treatment in patients with erosive esophagitis: a randomized pilot study. Esophagus [Internet]. 2021;18(3):669-75. Disponible en: https://link.springer.com/10.1007/s10388-020-00798-7
-27. Haruma K, Kinoshita Y, Yao T, Kushima R, Akiyama J, Aoyama N, et al. Randomised clinical trial: 3-year interim analysis results of the VISION trial to evaluate the long-term safety of vonoprazan as maintenance treatment in patients with erosive oesophagitis. BMC Gastroenterol [Internet].2023;23(1):139. Disponible en: https://bmcgastroenterol.biomedcentral.com/articles/10.1186/s12876-023-02772-w
-28. Laine L, DeVault K, Katz P, Mitev S, Lowe J, Hunt B, et al. Vonoprazan Versus Lansoprazole for Healing and Maintenance of Healing of Erosive Esophagitis: A Randomized Trial. Gastroenterology [Internet].2023;164(1):61-71. Disponible en: https://linkinghub.elsevier.com/retrieve/pii/S0016508522011635
-29. Sakurai K, Suda H, Fujie S, Takeichi T, Okuda A, Murao T, et al. Short-Term Symptomatic Relief in Gastroesophageal Reflux Disease: A Comparative Study of Esomeprazole and Vonoprazan. Dig Dis Sci [Internet].2019;64(3):815-22. Disponible en: http://link.springer.com/10.1007/s10620-018-5365-0
-30. Oshima T, Arai E, Taki M, Kondo T, Tomita T, Fukui H, et al. Randomised clinical trial: vonoprazan versus lansoprazole for the initial relief of heartburn in patients with erosive oesophagitis. Aliment Pharmacol Ther [Internet].2019;49(2):140-6. Disponible en: https://onlinelibrary.wiley.com/doi/10.1111/apt.15062
-31. Mizuno H, Yamada K, Minouchi K, Kamiyamamoto S, Hinoue Y. Efficacy of vonoprazan for 24-week maintenance therapy of patients with healed reflux esophagitis refractory to proton pump inhibitors. Biomed Rep [Internet].2017;8(2):148-55. Disponible en: http://www.spandidos-publications.com/10.3892/br.2017.1035
-32. Iwakiri K, Sakurai Y, Shiino M, Okamoto H, Kudou K, Nishimura A, et al. A randomized, double-blind study to evaluate the acid-inhibitory effect of vonoprazan (20 mg and 40 mg) in patients with proton-pump inhibitor-resistant erosive esophagitis. Therap Adv Gastroenterol [Internet].2017;10(6):439-51. Disponible en: http://journals.sagepub.com/doi/10.1177/1756283X17705329
-33. Hoshino S, Kawami N, Takenouchi N, Umezawa M, Hanada Y, Hoshikawa Y, et al. Efficacy of Vonoprazan for Proton Pump Inhibitor- Resistant Reflux Esophagitis. Digestion [Internet]. 2017;95(2):156-61. Disponible en: https://www.karger.com/Article/FullText/456072
-34. Yamashita H, Kanamori A, Kano C, Hashimura H, Matsumoto K, Tsujimae M, et al. The Effects of Switching to Vonoprazan, a Novel Potassium-Competitive Acid Blocker, on Gastric Acidity and Reflux Patterns in Patients with Erosive Esophagitis Refractory to Proton Pump Inhibitors. Digestion [Internet]. 2017;96(1):52-9. Disponible en: https://www.karger.com/Article/FullText/478255
-35. Tanabe T, Hoshino S, Kawami N, Hoshikawa Y, Hanada Y, Takenouchi N, et al. Efficacy of long-term maintenance therapy with 10-mg vonoprazan for proton pump inhibitor-resistant reflux esophagitis. Esophagus [Internet].2019;16(4):377-81. Disponible en: http://link.springer.com/10.1007/s10388-019-00676-x
-36. Mizuno H, Nishino M, Yamada K, Kamiyamamoto S, Hinoue Y. Efficacy of Vonoprazan for 48-Week Maintenance Therapy of Patients with Healed Reflux Esophagitis. Digestion [Internet]. 2020;101(4):411-21. Disponible en: https://karger.com/doi/10.1159/000500399
-37. Ochiai Y, Iizuka T, Hoshihara Y, Suzuki Y, Hayasaka J, Nomura K, et al. Efficacy of Vonoprazan for Refractory Reflux Esophagitis after Esophagectomy. Digestive Diseases [Internet]. 2021;39(6):569-76. Disponible en: https://www.karger.com/Article/FullText/515146
-38. Hamada S, Ihara E, Ikeda H, Muta K, Ogino H, Chinen T, et al. Clinical Characterization of Vonoprazan-Refractory Gastroesophageal Reflux Disease. Digestion [Internet].2021;102(2):197-204. Disponible en: https://karger.com/doi/10.1159/000503340
-39. Kinoshita Y, Sakurai Y, Shiino M, Kudou K, Nishimura A, Miyagi T, et al. Evaluation of the Efficacy and Safety of Vonoprazan in Patients with Nonerosive Gastroesophageal Reflux Disease: A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study. Current Therapeutic Research [Internet]. 2016;81-82:1-7. Disponible en: https://linkinghub.elsevier.com/retrieve/pii/S0011393X1630100X
-40. Shinozaki S, Osawa H, Hayashi Y, Miura Y, Lefor A, Yamamoto H. Longterm vonoprazan therapy is effective for controlling symptomatic proton pump inhibitorresistant gastroesophageal reflux disease. Biomed Rep [Internet].2021;14(3):32. Disponible en: http://www.spandidos-publications.com/10.3892/br.2021.1408
-41. Fass R, Vaezi M, Sharma P, Yadlapati R, Hunt B, Harris T, et al. Randomised clinical trial: Efficacy and safety of https://onlinelibrary.wiley.com/doi/10.1111/apt.17728
-42. Gotoh Y, Ishibashi E, Honda S, Nakaya T, Noguchi C, Kagawa K, et al. Efficacy of vonoprazan for initial and maintenance therapy in reflux esophagitis, nonerosive esophagitis, and proton pump inhibitor-resistant gastroesophageal reflux disease. Medicine [Internet].2020;99(11):e19520. Disponible en: https://journals.lww.com/10.1097/MD.0000000000019520
-43. Abe Y, Koike T, Saito M, Okata T, Nakagawa K, Hatta W, et al. The Ameliorating Effect of Switching to Vonoprazan: A Novel Potassium-Competitive Acid Blocker in Patients with Proton Pump Inhibitor Refractory Non-Erosive Reflux Disease. Digestion [Internet].2021;102(3):480-8. Disponible en: https://karger.com/doi/10.1159/000506152
-44. Kawami N, Hoshino S, Hoshikawa Y, Tanabe T, Koeda M, Momma E, et al. Determinants of reflux perception in patients with non-erosive reflux disease who have reflux-related symptoms on potassium-competitive acid blocker therapy. Esophagus [Internet]. 2022;19(2):367-73. Disponible en: https://link.springer.com/10.1007/s10388-021-00889-z
-45. Murakami K, Sakurai Y, Shiino M, Funao N, Nishimura A, Asaka M. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study. Gut [Internet].2016;65(9):1439-46. Disponible en: https://gut.bmj.com/lookup/doi/10.1136/gutjnl-2015-311304
-46. Kiyotoki S, Nishikawa J, Sakaida I. Efficacy of Vonoprazan for Helicobacter pylori Eradication. Internal
Medicine [Internet].2020;59(2):153-61. Disponible en: https://www.jstage.jst.go.jp/article/internalmedicine/59/2/59_2521-18/_article
-47. Chey WD, Mégraud F, Laine L, López LJ, Hunt BJ, Howden CW. Vonoprazan Triple and Dual Therapy for Helicobacter pylori Infection in the United States and Europe: Randomized Clinical Trial. Gastroenterology [Internet].2022;163(3):608-19. Disponible en: https://linkinghub.elsevier.com/retrieve/pii/S0016508522006096
-48. Jung YS, Kim EH, Park CH. Systematic review with meta-analysis: the efficacy of vonoprazan-based triple therapy on Helicobacter pylori eradication. Aliment Pharmacol Ther [Internet]. 2017;46(2):106-14. Disponible en: https://onlinelibrary.wiley.com/doi/10.1111/apt.14130
-49. Dong SQ, Singh TP, Wei X, Yao H, Wang HL. Review: A Japanese population-based meta-analysis of vonoprazan versus PPI for Helicobacter pylori eradication therapy: Is superiority an illusion? Helicobacter [Internet].2017;22(6). Disponible en: https://onlinelibrary.wiley.com/doi/10.1111/hel.12438
-50. Kim DK, Lee KH, Kim S jun, Kim SJ, Lee SJ, Park CH, et al. Effects of Tegoprazan, a Novel Potassium-Competitive Acid Blocker, on Rat Models of Gastric Acid-Related Disease. Journal of Pharmacology and Experimental Therapeutics [Internet]. 2019;369(3):318-27. Disponible en: http://jpet.aspetjournals.org/lookup/doi/10.1124/jpet.118.254904
-51. Tanaka S, Morita M, Yamagishi T, Madapally HV, Hayashida K, Khandelia H, et al. Structural Basis for Binding of Potassium-Competitive Acid Blockers to the Gastric Proton Pump. J Med Chem [Internet].2022;65(11):7843-53. Disponible en: https://pubs.acs.org/doi/10.1021/acs.jmedchem.2c00338
-52. Kim SH, Cho KB, Chun HJ, Lee SW, Kwon JG, Lee DH, et al. Randomised clinical trial: comparison of tegoprazan and placebo in non-erosive reflux disease. Aliment Pharmacol Ther [Internet].2021;54(4):402-11. Disponible en: https://onlinelibrary.wiley.com/doi/10.1111/apt.16477
-53. Jeong HC, Kim MG, Wei Z, Lee KR, Lee J, Song IS, et al. Integration of a Physiologically Based Pharmacokinetic and Pharmacodynamic Model for Tegoprazan and Its Metabolite: Application for Predicting Food Effect and Intragastric pH Alterations. Pharmaceutics [Internet]. 2022;14(6):1298. Disponible en: https://www.mdpi.com/1999-4923/14/6/1298
-54. Yoon DY, Lee S, Jang IJ, Kim M, Lee H, Kim S, et al. Prediction of Drug-Drug Interaction Potential of Tegoprazan Using Physiologically Based Pharmacokinetic Modeling and Simulation. Pharmaceutics [Internet].021;13(9):1489. Disponible en: https://www.mdpi.com/1999-4923/13/9/1489
-55. Jeon JY, Kim SY, Moon SJ, Oh K, Lee J, Kim B, et al. Pharmacokinetic Interactions between Tegoprazan and Metronidazole/ Tetracycline/Bismuth and Safety Assessment in Healthy Korean Male Subjects. Clin Ther [Internet].2021;43(4):722-34.
Disponible en: https://linkinghub.elsevier.com/retrieve/pii/S0149291821000539
-56. Kim MG, Im YJ, Lee JH, Kim EY, Yeom SW, Kim JS. Comparison of hepatotoxicity of tegoprazan, a novel potassium-competitive acid blocker, with proton pump inhibitors using real-world data: A nationwide cohort study. Front Med (Lausanne) [Internet].2023;9. Disponible en: https://www.frontiersin.org/articles/10.3389/fmed.2022.1076356/full
-57. Shin CM, Choi SC, Cho JW, Kim SY, Lee OJ, Kim DH, et al. 941 COMPARISON OF TEGOPRAZAN AND LANSOPRAZOLE IN PATIENTS WITH EROSIVE ESOPHAGITIS: A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, ACTIVE-COMPARATOR PHASE 4 TRIAL. Gastroenterology [Internet].2023;164(6):S-204. Disponible en: https://linkinghub.elsevier.com/retrieve/pii/S001650852301449X
-58. Lee KJ, Son BK, Kim GH, Jung H, Jung H, Chung I, et al. Randomised phase 3 trial: tegoprazan, a novel potassium-competitive acid blocker, vs. esomeprazole in patients with erosive oesophagitis. Aliment Pharmacol Ther [Internet]. 2019;49(7):864-72. Disponible en: https://onlinelibrary.wiley.com/doi/10.1111/apt.15185
-59. Cho YK, Kim JH, Kim H, Kim T, Oh J, Choi SC, et al. Randomised clinical trial: comparison of tegoprazan and lansoprazole as maintenance therapy for healed mild erosive oesophagitis. Aliment Pharmacol Ther [Internet]. 2023;57(1):72-80. Disponible en: https://onlinelibrary.wiley.com/doi/10.1111/apt.17255
-60. Kim JS, Seo SI, Kang SH, Lee SK, Kim AR, Park HW, et al. Effects of Tegoprazan Versus Esomeprazole on Nighttime Heartburn and Sleep Quality in Gastroesophageal Reflux Disease: A Multicenter Double-blind Randomized Controlled Trial. J Neurogastroenterol Motil [Internet]. 2023;29(1):58-64. Disponible en: http://www.jnmjournal.org/journal/view.html?-doi=10.5056/jnm22104
-61. Han S, Choi HY, Kim YH, Choi S, Kim S, Nam JY, et al. Comparison of Pharmacodynamics between Tegoprazan and Dexlansoprazole Regarding Nocturnal Acid Breakthrough: A Randomized Crossover Study. Gut Liver [Internet].2023;17(1):92-9. Disponible en: http://gutnliver.org/journal/view.html?doi=10.5009/gnl220050
-62. Yang E, Kim S, Kim B, Kim B, Kim Y, Park SS, et al. Night-time gastric acid suppression by tegoprazan compared to vonoprazan or esomeprazole. Br J Clin Pharmacol [Internet].2022;88(7): 3288-96. Disponible en: https://bpspubs.onlinelibrary.wiley.com/doi/10.1111/bcp.15268
-63. Kim SH, Cho KB, Chun HJ, Lee SW, Kwon JG, Lee DH, et al. Randomised clinical trial: comparison of tegoprazan and placebo in non-erosive reflux disease. Aliment Pharmacol Ther [Internet]. 2021;54(4):402-11. Disponible en: https://onlinelibrary.wiley.com/doi/10.1111/apt.16477
-64. Park CH, Park JH, Jung YS. Comparative Efficacy of Tegoprazan vs Esomeprazole/Sodium Bicarbonate for the Treatment of Helicobacter pylori Infection. Clin Transl Gastroenterol [Internet]. 023;14(11):e00632. Disponible en: https://journals.lww.com/10.14309/ctg.0000000000000632
-65. Kwon YH, Jeon SW, Nam SY, Lee DW, Park JH, Bae HJ. Tenday tegoprazan-based concomitant therapy as a first-line treatment for Helicobacter pylori eradication. Korean J Intern Med [Internet].2023;38(4):493-503. Disponible en: http://kjim.org/journal/view.php?doi=10.3904/kjim.2022.345
-66. Kim JS, Ko W, Chung J, Kim TH. Efficacy of tegoprazan-based bismuth quadruple therapy compared with bismuth quadruple therapy for Helicobacter pylori infection: A randomized, double-blind, active-controlled study. Helicobacter [Internet]. 2023;28(3). Disponible en: https://onlinelibrary.wiley.com/doi/10.1111/hel.12977
-67. Jung YS, Kim S, Kim HY, Noh SJ, Park JH, Sohn C Il, et al. Efficacy and Tolerability of 14-Day Tegoprazan- versus Rabeprazole-Based Triple Therapy for Eradication of Helicobacter pylori: A Real-World Evidence Study. Gut Liver [Internet]. 2023;17(5):711-21. Disponible en: http://gutnliver.org/journal/view.html?doi=10.5009/gnl220218
-68. Park CH, Song MJ, Jung BW, Park JH, Jung YS. Comparative Efficacy of 14-Day Tegoprazan-Based Triple vs. 10-Day Tegoprazan-Based Concomitant Therapy for Helicobacter pylori Eradication. J Pers Med [Internet].2022;12(11):1918. Disponible en: https://www.mdpi.com/2075-4426/12/11/1918
-69. Jung YS, Kim S, Kim H, Noh SJ, Park JH, Park CH. 7-day versus 14-day tegoprazan-based triple therapy to treat Helicobacter pylori infection: Real-world evidence. J Gastroenterol Hepatol [Internet].2022;37(10):1911-8. Disponible en: https://onlinelibrary.wiley.com/doi/10.1111/jgh.15939
-70. Choi YJ, Lee YC, Kim JM, Kim J Il, Moon JS, Lim YJ, et al. Triple Therapy-Based on Tegoprazan, a New Potassium-Competitive Acid Blocker, for First-Line Treatment of Helicobacter pylori Infection: A Randomized, Double-Blind, Phase III, Clinical Trial. Gut Liver [Internet].2022;16(4):535-46. Disponible en: http://gutnliver.org/journal/view.html?-doi=10.5009/gnl220055
-71. Kim JY, Lee SY, Kim H, Kim JH, Sung IK, Park HS. Efficacy of Seven-Day Potassium-Competitive Acid Blocker-Based First-Line Helicobacter Pylori Eradication Therapy Administered with Bismuth. Yonsei Med J [Internet]. 2021;62(8):708. Disponible en: https://eymj.org/DOIx.php?id=10.3349/ymj.2021.62.8.708
-72. Sunwoo J, Oh J, Moon SJ, Ji SC, Lee SH, Yu K -S., et al. Safety, tolerability, pharmacodynamics and pharmacokinetics of DWP 14012, a novel potassium-competitive acid blocker, in healthy male subjects. Aliment Pharmacol Ther [Internet]. 2018;48(2):206-18. Disponible en: https://onlinelibrary. wiley.com/doi/10.1111/apt.14818
-73. Jeong YS, Kim MS, Lee N, Lee A, Chae YJ, Chung SJ, et al. Development of Physiologically Based Pharmacokinetic Model for Orally Administered Fexuprazan in Humans. Pharmaceutics [Internet]. 2021;13(6):813. Disponible en: https://www.mdpi.com/1999-4923/13/6/813
-74. Shin W, Yang AY, Park H, Lee H, Yoo H, Kim A. A Comparative Pharmacokinetic Study of Fexuprazan 10 mg: Demonstrating Bioequivalence with the Reference Formulation and Evaluating Steady State. Pharmaceuticals [Internet]. 2023;16(8):1141. Disponible en: https://www.mdpi.com/1424-8247/16/8/1141
-75. Ramani A, Merchant A, Cash BD. Review of the clinical development of fexuprazan for gastroesophageal reflux–related disease. Eur J Clin Pharmacol [Internet].2023;79(8):1023-9. Disponible en: https://link.springer.com/10.1007/s00228-023-03521-4
-76. Lee KN, Lee OY, Chun HJ, Kim J Il, Kim SK, Lee SW, et al. Randomized controlled trial to evaluate the efficacy and safety of fexuprazan compared with esomeprazole in erosive esophagitis. World J Gastroenterol [Internet].2022;28(44):6294-309. Disponible en: https://www.wjgnet.com/1007-9327/full/v28/i44/6294.htm
-77. Hwang JG, Jeon I, Park SA, Lee A, Yu K, Jang I, et al. Pharmacodynamics and pharmacokinetics of DWP14012 (fexuprazan) in healthy subjects with different ethnicities. Aliment Pharmacol Ther [Internet].2020;52(11-12):1648-57. Disponible en: https://onlinelibrary.wiley.com/doi/10.1111/apt.16131
-78. Zhuang Q, Liao A, He Q, Liu C, Zheng C, Li X, et al. The efficacy and safety of fexuprazan in treating erosive esophagitis: a phase III, randomized, double-blind, multicenter study. J Gastroenterol Hepatol [Internet].2024;39(4):658-66. Disponible en: https://onlinelibrary.wiley.com/doi/10.1111/jgh.16471
-79. Oh J, Yang E, Jang IJ, Lee H, Yoo H, Chung JY, et al. Pharmacodynamic and Pharmacokinetic Drug Interactions between Fexuprazan, a Novel Potassium-Competitive Inhibitor, and Aspirin, in Healthy Subjects. Pharmaceutics [Internet]. 2023;15(2):549. Disponible en: https://www.mdpi.com/1999-4923/15/2/549
-80. Zhuang Q, Liao A, He Q, Liu C, Zheng C, Li X, et al. The efficacy and safety of fexuprazan in treating erosive esophagitis: a phase III, randomized, double-blind, multicenter study. J Gastroenterol Hepatol [Internet].2024;39(4):658-66. Disponible en: https://onlinelibrary.wiley.com/doi/10.1111/jgh.16471
-81. Lee KN, Lee OY, Chun HJ, Kim J Il, Kim SK, Lee SW, et al. Randomized controlled trial to evaluate the efficacy and safety of fexuprazan compared with esomeprazole in erosive esophagitis. World J Gastroenterol [Internet].2022;28(44):6294-309. Disponible en: https://www.wjgnet.com/1007-9327/full/v28/i44/6294.htm
-82. Kim GH, Choi MG, Kim J Il, Lee ST, Chun HJ, Lee KL, et al. Efficacy and Safety of Fexuprazan in Patients with Acute or Chronic Gastritis. Gut Liver [Internet].2023;17(6):884-93. Disponible en: http://gutnliver.org/journal/view.html?doi=10.5009/gnl220457
-83. Yu K, Bae K, Shon J, Cho J, Yi S, Chung J, et al. Pharmacokinetic and Pharmacodynamic Evaluation of a Novel Proton Pump Inhibitor, YH1885, in Healthy Volunteers. The Journal of Clinical Pharmacology [Internet].2004;44(1):73-82. Disponible en: https://accp1.onlinelibrary.wiley.com/doi/10.1177/0091270003261321
-84. Kim H, Park S, Cheung D, Cho Y, Kim J, Kim S, et al. Clinical trial: Inhibitory effect of revaprazan on gastric acid secretion in healthy male subjects. J Gastroenterol Hepatol [Internet]. 2010;25(10):1618-25. Disponible en: https://onlinelibrary.wiley.com/doi/10.1111/j.1440-1746.2010.06408.x
-85. Sunwoo J, Ji SC, Oh J, Ban MS, Nam JY, Kim B, et al. Pharmacodynamics of tegoprazan and revaprazan after single and multiple oral doses in healthy subjects. Aliment Pharmacol Ther [Internet].2020;52(11-12):1640-7. Disponible en: https://onlinelibrary.wiley.com/doi/10.1111/apt.16121
-86. Park JH, Cho JH, Kim DS, Kim JS, Din FU, Kim JO, et al. Revaprazan-loaded surface-modified solid dispersion: physicochemical characterization and in vivo evaluation. Pharm Dev Technol [Internet].2019;24(6):788-93. Disponible en: https://www.tandfonline.com/doi/full/10.1080/10837450.2019.1597114
-87. Kim JS, Park JH, Jeong SC, Kim DS, Yousaf AM, Din FU, et al. Novel revaprazan-loaded gelatin microsphere with enhanced drug solubility and oral bioavailability. J Microencapsul [Internet].2018;35(5):421-7. Disponible en: https://www.tandfonline.com/doi/full/10.1080/02652048.2018.1515997
-88. Zhou S, Xie L, Zhou C, Wang L, Chen J, Ding S, et al. Keverprazan, a novel potassium-competitive acid blocker: Multiple oral doses safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy subjects. Clin Transl Sci [Internet]. 2023;16(10):1911-22. Disponible en: https://ascpt.onlinelibrary.wiley.com/doi/10.1111/cts.13598
-89. Zhou S, Xie L, Zhou C, Zhao Y, Wang L, Ding S, et al. Keverprazan, a novel potassium-competitive acid blocker: Single ascending dose safety, tolerability, pharmacokinetics, pharmacodynamics and food effect in healthy subjects. European Journal of Pharmaceutical Sciences [Internet].2023;190:106578. Disponible en: https://linkinghub.elsevier.com/retrieve/pii/S0928098723002087
-90. Tan N di, Miao X pu, Liao A jun, Liu C xia, Wu H, Chen H hui, et al. Efficacy and Safety of Keverprazan Compared with Lansoprazole in the Treatment of Duodenal Ulcer: A Phase III, Randomized, Double-Blind, Multicenter Trial. Clin Transl Gastroenterol [Internet].2023;14(7):e00602. Disponible en: https://journals.lww.com/10.14309/ctg.0000000000000602
-91. Tan N, Liu X, Liu C, Li S, Chen H, Li X, et al. Efficacy of keverprazan for duodenal ulcer: A phase II randomized, double-blind, parallel-controlled trial. J Gastroenterol Hepatol [Internet].2022;37(11):2060-6. Disponible en: https://onlinelibrary.wiley.com/doi/10.1111/jgh.16000
-92. Chen S, Liu D, Chen H, Liao A, Li F, Liu C, et al. The efficacy and safety of keverprazan, a novel potassium-competitive acid
blocker, in treating erosive oesophagitis: a phase III, randomised, double-blind multicentre study. Aliment Pharmacol
Ther [Internet].2022;55(12):1524-33. Disponible en: https://onlinelibrary.wiley.com/doi/10.1111/apt.16959
-93. Hwang I, Ji SC, Oh J, Kim H, Cha H, Kim J, et al. Randomised clinical trial: Safety, tolerability, pharmacodynamics and pharmacokinetics of zastaprazan (JP-1366), a novel potassium-competitive acid blocker, in healthy subjects. Aliment Pharmacol Ther [Internet]. 2023;57(7):763-72. Disponible en: https://onlinelibrary.wiley.com/doi/10.1111/apt.17406
Publicado
Cómo citar
Número
Sección
Licencia
Derechos de autor 2024 José M. Remes-Troche, José Luis Vargas-Basurto, Luis Valdovinos-García
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-CompartirIgual 4.0.
